$1.8M R&D Rebate Received
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Biotron Limited has announced the receipt of an R&D Tax Incentive rebate for the financial year. The rebate amounts to a significant sum and is part of an Australian Government program that supports research and development expenditures. This funding is linked to Biotron's antiviral drug development initiatives. The announcement highlights Biotron's ongoing commitment to addressing viral diseases with unmet medical needs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Biotron
- BIT225-012 Phase 2 COVID-19 clinical trial
- BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives
- Positive outcomes in BIT225 phase 2 clinical trial in hiv
- Response to ASX Price Query
- Completion of Phase 2 COVID clinical trial
Later from Biotron
- Agreement with C14 Consulting Group
- Updated Appendix 4C
- Renounceable Rights Issue
- Prospectus
- Response to ASX Aware Query
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron